By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Animal biotechnology firm MetaMorphix today announced the sale of its assets as part of its Chapter 11 bankruptcy filing.

The sale is for both its businesses, one directed at animal genomics, the other at growth and differentiation factors. American MedTech Advisors is advising the Calverton, MD.-based firm on the sale.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.